Clinical study for children with Dup15q Syndrome

The Quindecim clinical research study, sponsored by a pharmaceutical company called Roche, is testing the medication Basmisanil in children with Dup15q Syndrome.

Basmisanil is a drug that modulates the activity of a GABAA receptor subtype that is thought to be overactive in dup15q syndrome. In this trial, researchers aim to find out what effects, good or bad, Basmisanil may have compared to a placebo, on motor, language, and social skills of children with Dup15q syndrome and on their ability to do day-to-day activities.

Watch the conference replay below with Dr. Shafali Jeste to learn more about GABAA in dup15q and the dup15q eeg biomarker. 

 

Enrollment

Quindecim study is currently running and plans to include about 90 children with Dup15q syndrome, between the ages of 2 and 11 years old (inclusive) some locations are enrolling ages 2-14. 
Important: If your child does not meet current eligibility requirements, please check back as it is projected two additional groups may open.

For General Questions call 1-888-662-6728.

 

Current US Locations Enrolling: *more locations expected to open in 2023

RUSH University Medical Center in Chicago
1620 W. Harrison St., Chicago, IL 60612

 

Currently enrolling ages 2 – 14. Interested in Enrolling at Rush?
Contact Margaret_R_Porwit@rush.edu

University of North Carolina at Chapel Hill

 

Currently enrolling ages 2 – 11. Interested in Enrolling at UNC?
Contact victoria_banks@neurology.unc.edu
Phone: (919) 962-5137

Children’s Hospital Los Angeles 
4650 W Sunset Blvd, Los Angeles, CA 90027

 

Currently enrolling ages 2 – 11. Interested in Enrolling at CHLA?
Contact nagonzalez@chla.usc.edu

Rady Children’s Hospital San Diego
3020 Children’s Way, San Diego, CA 92123

 

Currently enrolling ages 2 – 14. Interested in Enrolling at Rady?
Contact: mnsuarez@rchsd.org
Phone: 858.576.1700 Ext: 226134

Learn More

To learn more about the study, please talk to your doctor and check the following resources:

Study: Clinical Trial – Dup15q Syndrome – Safety, Efficacy, and Pharmacodynamics of Basmisanil | ForPatients-Roche

Dup15q Clinical Trial Guide

Roche Pharmaceutical: Drug Trial Update with Dr. Eugenie Suter

How is the Dup15q EEG Biomarker connected to this Clinical Trial?

Dup15q Alliance is not affiliated with, nor has any financial investment in these Studies. Dup15q Alliance is sharing information about these external partner opportunities, and is not sponsoring nor is directly involved in these partner projects. Should you choose to reach out to any of the Studies and/or become involved, you would do so independently from Dup15q Alliance.